recovery following heavy, chronic infestations. While public forest managers have alternative protection measures available, implementation of these protection measures is costly and the economic benefits of protecting hemlock health are largely unknown.

Eastern hemlock forests provide a suite of public and private goods that have economic value, including wildlife habitat, aesthetic landscapes, and commercial timber. In addition, hemlock forests located on public land provide unique natural settings for recreational activities, provide habitat for many species of wildlife, and help prevent soil erosion along the banks of streams and rivers. As the impacts of this invasion accrue, forest managers' demand for information increases.

Forest Service and university researchers will collect and analyze information regarding the value of the ecosystem services provided by hemlock forests located on public land in the Southern Appalachian Mountains from residents living within 500 miles of Asheville, North Carolina. The data and analyses will provide guidance to public forest managers regarding the value of ecosystem services supplied by hemlock forests on the land that they manage and the level of public support for alternative hemlock forest-protection programs.

Telephone interviewers will contact individual head-of-households via random digit dialing. Those agreeing to participate will receive a questionnaire via the United States Postal Service, along with a cover letter describing the purpose of the study, information about current hemlock forest conditions in Southern Appalachian Mountain public forests, and available protection alternatives. Approximately two weeks after receiving the questionnaire, respondents will share answers via telephone interview.

Estimate of Annual Burden: 45 minutes.

Type of Respondents: Individuals, heads of households.

Estimated Annual Number of Respondents: 500.

Estimated Annual Number of Responses per Respondent: 1. Estimated Total Annual Burden on

Respondents: 375 hours.

## **Comment Is Invited**

Comment is invited on: (1) Whether this collection of information is necessary for the stated purposes and the proper performance of the functions of the agency, including whether the information will have practical or scientific utility; (2) the accuracy of the agency's estimate of the burden of the

collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

All comments received in response to this notice, including names and addresses when provided, will be a matter of public record. Comments will be summarized and included in the submission request toward Office of Management and Budget approval.

Dated: June 23, 2008.

#### David A. Cleaves,

Associate Deputy Chief, Research and Development.

[FR Doc. E8–14552 Filed 6–25–08; 8:45 am] BILLING CODE 3410–11–P

## **DEPARTMENT OF COMMERCE**

# Foreign–Trade Zones Board (Docket 41–2008)

Foreign-Trade Zone 7 - Mayaguez, Puerto Rico, Application for Subzone, Amgen Manufacturing Limited, (Biotechnology and Healthcare Products), Juncos, Puerto Rico

An application has been submitted to the Foreign-Trade Zones Board (the Board) by the Puerto Rico Industrial Development Company, grantee of FTZ 7, requesting special-purpose subzone status for the manufacture of biotechnology and healthcare products at the facility of Amgen Manufacturing Limited (Amgen), located in Juncos, Puerto Rico. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a-81u), and the regulations of the Board (15 CFR part 400). It was formally filed on June 19, 2008.

The Amgen facility (2,000 employees, 28 buildings with 1,900,718 square feet on 221 acres) is located at Road PR 31 Km. 24.6, in Juncos, Puerto Rico. The facility will be used to manufacture, test, package and warehouse Epogen®, (Epoetin Alfa), Neupogen® (Filgrastim), Aransep® (Darbepoetin Alfa), Enbrel® (Etanercept), Kineret® (Anakinra), and Neulasta® (Pegfilgrastim) (duty–free). Components and materials sourced from abroad (representing 2% of the value of the finished product) include: vials, syringes, stoppers, plunger rods,

partitions and dispenser packs (HTSUS duty rate ranges from duty–free to 2.7%).

FTZ procedures would exempt Amgen from customs duty payments on the foreign components used in export production. The company anticipates that some 48 percent of the plant's shipments will be exported. On its domestic sales, Amgen could choose the duty–free rate during customs entry procedures that applies to finished biotechnology and healthcare products for the foreign inputs noted above. The request indicates that the savings from FTZ procedures would help improve the plant's international competitiveness.

In accordance with the Board's regulations, Elizabeth Whiteman of the FTZ staff is designated examiner to investigate the application and report to the Board.

Public comment is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board's Executive Secretary at the address below. The closing period for their receipt is August 25, 2008. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15–day period to September 9, 2008.

A copy of the application and accompanying exhibits will be available for public inspection at each of the following locations:
U.S. Department of Commerce Export Assistance Center, Tower II Suite 702, Road 165, Guaynabo, Puerto Rico 00968. Office of the Executive Secretary, Foreign—Trade Zones Board, U.S. Department of Commerce, Room 2111, 1401 Constitution Ave. NW,

For further information, contact Elizabeth Whiteman at Elizabeth Whiteman@ita.doc.gov or (202) 482–0473.

Dated: June 19, 2008.

Washington, DC 20230.

# Andrew McGilvray,

Executive Secretary.

[FR Doc. E8–14537 Filed 6–25–08; 8:45 am] BILLING CODE 3510–DS–S

# **DEPARTMENT OF COMMERCE**

## **Bureau of Industry and Security**

Emerging Technology and Research Advisory Committee; Notice of Recruitment of Private-Sector Members Date Extension

The Bureau of Industry and Security (BIS) is announcing the creation of and recruiting individuals for a technical